SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (1194)6/14/1997 1:35:00 AM
From: Vector1   of 9719
 
Max, and Andrew you asked why we bought CLTR. I am the bull on this one. The Coulter management team is very experienced and very smart. Low grade NHL is the disease to go after because it is the most resistent to Chemo. Medium and High grade respond effectively in 50% of the cases. These form of the disease progess much more quickly but can be treated with conventional chemo with some success. Low grade NHL patients develop resistence to chemo after a relapse or two. The patients in Coulters trial have become resistent to chemo and have absolutely no alternatives. That is why the success rate that was achieve is so remarkable. It also fits in with their quick approval strategy which requires the FDA to expedite approval of drugs for patients with no other options.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News